Bapi Pahar1, Angela M Amedee, Jessica Thomas, Jason P Dufour, Ping Zhang, Steve Nelson, Ronald S Veazey, Gregory J Bagby. 1. *Division of Comparative Pathology, Tulane National Primate Research Center, Covington, LA; Departments of †Physiology; ‡Medicine, Louisiana State University Health Sciences Center, New Orleans, LA; and §Department of Surgery, Michigan State University College of Human Medicine, East Lansing, MI.
Abstract
BACKGROUND: Simian immunodeficiency virus (SIV) infection in macaques chronically receiving ethanol results in significantly higher plasma viral loads and more rapid progression to end-stage disease. We thus hypothesized that the increased plasma viral load in ethanol-treated, SIV-infected macaques would negatively correlate with antigen-specific immune responses. METHODS: Rhesus macaques were administered ethanol or sucrose (n = 12 per group) by indwelling gastric catheters for 3 months and then intravenously infected with SIVMAC251. Peripheral blood T- and B-cell immunophenotyping and quantification were performed. Plasma was examined for viremia, levels of SIVEnv-specific binding, and neutralizing antibodies. Virus-specific interferon γ and tumor necrosis factor α cytokine responses to SIV-Nef, Gag, or Env peptide pools were measured in peripheral blood CD8 T cells. RESULTS: Macaques receiving ethanol had both higher plasma viremia and virus-specific cellular immune responses compared with the sucrose-treated group. The emergence of virus-specific cytokine responses temporally correlated with the decline in mean plasma viral load after 14 days postinfection in all SIV-infected animals. However, neither the breadth and specificity nor the magnitude of virus-specific CD8 T-cell responses correlated with early postpeak reductions in plasma viral loads. In fact, increased cytokine responses against Gag, gp120, and gp41 positively correlated with plasma viremia. Levels of SIV envelope-specific immunoglobulin G and neutralizing antibodies were similar over the disease course in both groups of macaques. CONCLUSIONS: Persistently higher antigen-specific cytokine responses in animals receiving ethanol are likely an effect of the higher viral loads and antigen persistence, rather than a cause of the increased viremia.
BACKGROUND:Simian immunodeficiency virus (SIV) infection in macaques chronically receiving ethanol results in significantly higher plasma viral loads and more rapid progression to end-stage disease. We thus hypothesized that the increased plasma viral load in ethanol-treated, SIV-infected macaques would negatively correlate with antigen-specific immune responses. METHODS:Rhesus macaques were administered ethanol or sucrose (n = 12 per group) by indwelling gastric catheters for 3 months and then intravenously infected with SIVMAC251. Peripheral blood T- and B-cell immunophenotyping and quantification were performed. Plasma was examined for viremia, levels of SIVEnv-specific binding, and neutralizing antibodies. Virus-specific interferon γ and tumornecrosis factor α cytokine responses to SIV-Nef, Gag, or Env peptide pools were measured in peripheral blood CD8 T cells. RESULTS: Macaques receiving ethanol had both higher plasma viremia and virus-specific cellular immune responses compared with the sucrose-treated group. The emergence of virus-specific cytokine responses temporally correlated with the decline in mean plasma viral load after 14 days postinfection in all SIV-infected animals. However, neither the breadth and specificity nor the magnitude of virus-specific CD8 T-cell responses correlated with early postpeak reductions in plasma viral loads. In fact, increased cytokine responses against Gag, gp120, and gp41 positively correlated with plasma viremia. Levels of SIV envelope-specific immunoglobulin G and neutralizing antibodies were similar over the disease course in both groups of macaques. CONCLUSIONS: Persistently higher antigen-specific cytokine responses in animals receiving ethanol are likely an effect of the higher viral loads and antigen persistence, rather than a cause of the increased viremia.
Authors: J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis Journal: Nat Med Date: 2000-02 Impact factor: 53.440
Authors: M R Betts; D R Ambrozak; D C Douek; S Bonhoeffer; J M Brenchley; J P Casazza; R A Koup; L J Picker Journal: J Virol Date: 2001-12 Impact factor: 5.103
Authors: Frank H Galvan; Eric G Bing; John A Fleishman; Andrew S London; Raul Caetano; M Audrey Burnam; Doug Longshore; Sally C Morton; Maria Orlando; Martin Shapiro Journal: J Stud Alcohol Date: 2002-03
Authors: P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton Journal: J Virol Date: 2001-09 Impact factor: 5.103
Authors: Ronald S Veazey; Robin J Shattock; Melissa Pope; J Christian Kirijan; Jennifer Jones; Qinxue Hu; Tom Ketas; Preston A Marx; Per Johan Klasse; Dennis R Burton; John P Moore Journal: Nat Med Date: 2003-02-10 Impact factor: 53.440
Authors: Gregory J Bagby; David A Stoltz; Ping Zhang; Jay K Kolls; Julie Brown; Rudolf P Bohm; Richard Rockar; Jeanette Purcell; Michael Murphey-Corb; Steve Nelson Journal: Alcohol Clin Exp Res Date: 2003-03 Impact factor: 3.455
Authors: Xu Wang; Steven D Douglas; David S Metzger; Chang-Jiang Guo; Yuan Li; Charles P O'Brien; Li Song; Annet Davis-Vogal; Wen-Zhe Ho Journal: Alcohol Clin Exp Res Date: 2002-12 Impact factor: 3.455
Authors: Patricia E Molina; Angela M Amedee; Peter Winsauer; Steve Nelson; Gregory Bagby; Liz Simon Journal: J Neuroimmune Pharmacol Date: 2015-03-21 Impact factor: 4.147
Authors: Paige S Katz; Robert W Siggins; Connie Porretta; Megan L Armstrong; Arnold H Zea; Donald E Mercante; Christopher Parsons; Ronald S Veazey; Gregory J Bagby; Steve Nelson; Patricia E Molina; David A Welsh Journal: Alcohol Date: 2015-10-27 Impact factor: 2.405